

HEALTH PLAN POLICY	
Policy Title: Genetic Expression Profiling for Prostate Cancer	Policy Number: MUM57 Revision: New
Department: Medical Management	Sub-Department: Utilization Management
Applies to Product Lines: <input type="checkbox"/> Medicaid <input checked="" type="checkbox"/> USFHP <input type="checkbox"/> Children's Health Insurance Plan <input checked="" type="checkbox"/> Commercial Insured <input checked="" type="checkbox"/> Health Insurance Exchange <input type="checkbox"/> Non Insured Business <input checked="" type="checkbox"/> Medicare	
Origination/Effective Date: 10/09/2019	
Reviewed Date(s):	Revision Date(s):

SCOPE:

This policy addresses genetic expression profiling (GEP) for prostate cancer.

DEFINITIONS AND ACRONYMS:

- American Society of Clinical Oncology (ASCO)
- Digital Rectal Exam (DRE)
- Genetic Expression Profiling (GEP)
- National Comprehensive Care Network (NCCN)
- Prostate Specific Antigen (PSA)

POLICY:

GEP is investigational and lacks medical necessity for detection and/or management of prostate cancer.

RATIONALE:

Prostate cancer is the most common male malignancy and the second most likely source of male death from cancer. Extensive research surrounding gene based testing for prostate disease has been done. To date no evidence based literature supports clinical value in most prostate disease. PSA and DRE are currently the only tests of value in this area broadly.

In 2012, the FDA approved PCA-3 as a genetic tool for a specific subclass of patients with prior negative prostate biopsies over the age of 50, and then only in conjunction with other studies. Problems with PCA-3 include false positive and false negative results that lead either to overutilization of prostate biopsies or failure to perform prostate biopsies, according to the FDA.

The NCCN in 2019 has not considered biomarkers as first line screening tests. ASCO in 2018 did not endorse genetic biomarkers as having a clear role in prostate disease.

HEALTH PLAN POLICY

Policy Title: Genetic Expression Profiling for Prostate Cancer

Policy Number: MUM57
Revision: New

REFERENCES:

- NCCN 2019 Biomarkers as Screening Tests
- ASCO 2018 Biomarkers in Prostate Disease

RELATED DOCUMENTS:


None



Nancy Horstmann
Chief Executive Officer Health Plans

10/10/19

Date



David W. Engleking, MD
Medical Director

10/15/19

Date

REVISION HISTORY:

Revision	Date	Description of Change	Committee
New	10/09/2019	Initial release.	Executive Leadership